• Friday, September 16, 2022 @ 12:00 am

Cosmo reported its best half-year in terms of revenues with Winlevi off to an excellent start attracting partnering agreements, while legacy products rebounded strongly. Cosmo’s investments to move towards large markets are starting to pay off, with GI Genius and Winlevi just beginning to gain traction.

Key catalysts include:

1. Start Breezula phase III in male alopecia (Q4 2022)
2. Start Aemcolo phase III in IBS-D (Q4 2022)
3. Start confirmatory Lumeblue phase III for US approval (Q4 2022)

Read the full report

You may also be interested in